NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48% clinical benefit rate at or above the therapeutic dose threshold along with a favorable safety profile and strong biomarker correlations. The company also outlined plans for Phase 1b/2 studies in TNBC, NSCLC with STK11/KEAP1 co-mutations, and bladder cancer, supported by pharmacokinetic data establishing a recommended Phase 2 dose of 0.39 mg/kg. Lantern noted catalyst-rich progress across its pipeline, including regulatory clarity for its pediatric CNS…







